‘Genetic Fingerprint’ Said to Help Identify Aggressive Cancer, Could Lead to Personalized Treatments

‘Genetic Fingerprint’ Said to Help Identify Aggressive Cancer, Could Lead to Personalized Treatments
Researchers have uncovered a "genetic fingerprint" that could help doctors identify a form of prostate cancer that spreads aggressively after radiotherapy or surgery, and is found in 30% of patients with potentially, curable localized disease. The findings, detailed in the study "Genomic hallmarks of localized, non-indolent prostate cancer" and published in Nature, could lead to the development of better, personalized therapies that improve cure rates in prostate cancer patients. Researchers at the Princess Margaret Cancer Centre, University Health Network, set out to document the genetic profile of prostate cancer patients who respond differently to therapies. They began by examining the tumors of 500 Canadian men with localized, non-inherited prostate cancer who had similar clinical risk profiles. "We used specialized state-of-the-art DNA sequencing techniques to focus on the genetics of prostate cancers to better understand what is so different from one man's disease to another man's disease," Robert Bristow, MD, PhD, clinician-scientist at the Princess Margaret Cancer Centre, said in a press release. The team found a number of molecular alterations that could be used as prognostic factors, including changes in the epigenetic signature. (Prognostic factors are situations or conditions, or a charac
Subscribe or to access all post and page content.

One comment

  1. Lawrence Glickman says:

    The current genetic available test PCA3
    Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer.[2][3] Because of its restricted expression profile, the PCA3 RNA is useful as a tumor marker.[4]

Leave a Comment

Your email address will not be published. Required fields are marked *